AAV hmAb
Alternative Names: AAV mediated neurodegenerative disorders antibodyLatest Information Update: 03 Oct 2023
At a glance
- Originator Neurimmune Therapeutics
- Class Antidementias; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Alpha-synuclein modulators; Tau protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Neurodegenerative disorders
Most Recent Events
- 03 Oct 2023 Discontinued for Alzheimer's disease in Switzerland (Parenteral) (Neurimmune Therapeutics pipeline, October 2023)
- 03 Oct 2023 Discontinued for Neurodegenerative disorders in Switzerland (Parenteral) (Neurimmune Therapeutics pipeline, October 2023)
- 28 Aug 2023 No recent reports of development identified for research development in Alzheimer's-disease in Switzerland (Parenteral)